期刊
BLOOD REVIEWS
卷 32, 期 6, 页码 480-489出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2018.04.005
关键词
CD47; Immunotherapy; Apoptosis; Phagocytosis; Leukemic stem cell; Monoclonal antibody; Hematologic malignancy
类别
资金
- NCI NIH HHS [P30 CA023074] Funding Source: Medline
- NIGMS NIH HHS [R01 GM117357] Funding Source: Medline
Hematological malignancies express high levels of CD47 as a mechanism of immune evasion. CD47-SIRP alpha triggers a cascade of events that inhibit phagocytosis. Preclinical research supports several models of antibody mediated blockade of CD47-SIRP alpha resulting in cell death signaling, phagocytosis of cells bearing stress signals, and priming of tumor-specific T cell responses. Four different antibody molecules designed to target the CD47-SIRP alpha interaction in malignancy are currently being studied in clinical trials: Hu5F9-G4, CC-90002, TTI-621, and ALX-148. Hu5F9-G4, a humanized anti-CD47 blocking antibody is currently being studied in four different Phase I trials. These studies may lay the groundwork for therapeutic bispecific antibodies. Bispecific antibody (CD2O-CD47SL) fusion of anti-CD20 (Rituximab) and anti-CD47 also demonstrated a synergistic effect against lymphoma in preclinical models. This review summarizes the large body of preclinical evidence and emerging clinical data supporting the use of antibodies designed to target the CD47-SIRP alpha interaction in leukemia, lymphoma and multiple myeloma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据